DEBBANE RAYMOND
Director · LEXICON PHARMACEUTICALS, INC.
Every open-market stock purchase DEBBANE RAYMOND has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- LXRX+66.5% vs price paidLEXICON PHARMACEUTICALS, INC.
4 purchases totalling $572.2K at an average of $1.39 per share; the stock last traded at $2.32. See all insider buying in LXRX →
Avg price paid$1.39Latest price$2.32Market cap$1.0B
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving DEBBANE RAYMOND or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from DEBBANE RAYMOND's Form 4 filings on SEC EDGAR (CIK 1053890) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.